Description: XVIVO is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. Our mission is to increase the survival rates of patients awaiting transplantation by providing more effective, clinically proven innovative products that both increase the availability of acceptable donors organs and improve survival after transplantation. We are committed to provide our customers with solutions and systems that can improve the transplant process outcome, facilitate the work for the transplant team, and enhance the long-term outcomes and quality of life of the transplant recipient.
Home Page: www.xvivoperfusion.com
MAessans gata 10
Gothenburg,
412 51
Sweden
Phone:
46 3 17 88 21 50
Officers
| Name | Title |
|---|---|
| Mr. Christoffer Rosenblad | Chief Exec. Officer |
| Mr. Kristoffer Nordstrom | CFO & Investor Relations |
| Ms. Lena Hagman B.Sc. | Chief Operating Officer |
| Dr. Magnus Nilsson Ph.D. | Sr. Advisor |
| Ms. Katrin Gisselfalt Ph.D. | Global Quality Assurance & Regulatory Affairs Director |
| Mr. Andreas Wallinder M.D., Ph.D. | Chief Medical Officer |
| Mr. Johan Holmstrom | Chief Commercial Officer |
| Ms. Charlotte Walldal | Global R&D director |
| Jaya Tiwari | VP Clinical and Regulatory Affairs |
| Mr. Christer de Flon | Mang. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 93.4579 |
|---|---|
| Trailing PE: | 182 |
| Price-to-Book MRQ: | 4.5836 |
| Price-to-Sales TTM: | 16.9032 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 118 |